Orexo receives MGBP 5 milestone payment for Abstral® in

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 11, 2015 at 2:15 AM

Orexo receives MGBP 5 milestone payment for Abstral® in Europe and records OX-MPI non-cash impairment charge of MSEK 62

Uppsala, Sweden – December 11, 2015 – Orexo AB (publ) today announced that the annual sales of Abstral in Europe has passed MEUR 67.5 during 2015, which triggers a milestone payment of MGBP 5 (approx. MSEK 63.8) to Orexo AB (”Orexo”) from the commercial partner in Europe ProStrakan Group plc (”ProStrakan”). According to the agreement from June 2012, with ProStrakan for Abstral sales in Europe, Orexo receives a fixed and non-conditional royalty of MGBP 55, a variable royalty for annual sales exceeding MEUR 42.5 and milestone payments of up to MGBP 10. With the announced MGBP 5 milestone payment Orexo has earned all milestone payments associated with the ProStrakan European agreement. Orexo has further decided to record a non-cash charge of MSEK 62 related to an impairment of the OX-MPI asset. Orexo still considers OX-MPI an attractive asset and will continue the dialogue with potential partners, however as part of the annual impairment assessment it has been decided to fully write down the value of the asset. Both events will have full financial impact in the fourth quarter of 2015. ”I am pleased to follow the continued success of our commercial partner ProStrakan with Abstral in Europe. The performance of Abstral in Europe is a strong evidence of the patient and physician preference of the attributes of Orexo’s sublingual products and this performance enables Orexo to continue investing in the commercialization of Zubsolv® and in development of potential new formulation platforms,” said Nikolaj Sørensen, CEO and President of Orexo AB. For further information, please contact: Nikolaj Sørensen, CEO and President Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com Henrik Juuel, CFO and EVP Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com About Abstral® Abstral is the leading fast-acting fentanyl product in EU intended for treatment of breakthrough pain in cancer patients. Abstral employs Orexo’s proprietary sublingual delivery technology (under the tongue). After the product development Abstral was out-licensed to Kyowa Hakko Kirin Co., Ltd. and the European subsidiary ProStrakan Group plc, which still holds the rights in the Japan and EU respectively, whereas Sentynl Therapeutics Inc. holds the rights in the US. About OX-MPI The project aims to develop products based on specific inhibition of prostaglandin E2 (PGE2) in different disease conditions. Boehringer Ingelheim was since 2005 responsible for all research and development within the OX-MPI project. On August 6, 2014, Orexo announced that Boehringer Ingelheim had decided to return the project to Orexo. The project, and the intangible asset of MSEK 62, originates from the acquisition of Biolipox. About Zubsolv® ZUBSOLV (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the treatment of opioid dependence and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. To read more about Zubsolv, visit www.zubsolv.com To read more about opioid dependence, visit www.outthemonster.com About Orexo Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden. www.orexo.com Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 8:00 a.m. CET on December 11, 2015.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Inaugural Generator Tech Class Graduates from ASTA

New Talent Emerges in Power Sector In a landscape rife with labor shortages, five fresh-out-of-training generator technicians from the American Skilled Trades Academy (ASTA) are stepping onto the field, ready to fill some critical boots. PowerChampions, a power services outfit hell-bent on fixing the nation's generator woes, just graduated these folks from ASTA, its own...

OpenAI Expands ChatGPT Ads: Aleph Partnership Key

OpenAI Teams Up with Aleph for Global Reach OpenAI's no rookie in the tech game, but its move to bolster ChatGPT's ad presence with Aleph is like adding a rocket to turbocharge its engine. With Aleph as a partner, OpenAI's not just dipping a toe in the waters of global advertising—they're diving headfirst into 44 countries. This isn't just about slapping ads on more...

Coastal Financial Faces Class Action: Act By Dec 1

Stockholders Battle Erupts: Coastal Financial's Crisis Just when you think you've seen it all in this chaotic market, something like Coastal Financial Corporation's troubles hits you on a Tuesday afternoon like a sucker punch. If you've been dabbling with NASDAQ: CCB shares, heads-up—there's a December 1, 2026 deadline to potentially take the helm in a class action...

Mark Isham: Recognizing the Voice Behind Award Nomination

What's in a Name? Mark Isham Earns His Spotlight Hollywood’s buzz these days has less to do with the usual blockbuster glitter and more with a singular name cresting the scene: Mark Isham. You may not see his name in lights, and yet it’s blaring behind every soundtrack that brings a film to life. This time around, he's in the spotlight not for composing an...

AI Proving Grounds: Preemptive Security's Rise

Pushing Security to the Forefront The AI Proving Grounds Consortium (AIPGC) ain't just talking shop—they're tossing down the gauntlet. As cyber threats accelerate faster than my ticker can twitch, these experts are hollering for preemptive security measures. On September 24, the big wigs gathered to hash out why AI-fueled attacks demand we hit the gas on our defense...

Big Sipz Rides RTD Wave With Vodka-Based Lyte Ade

Cracking Into a New Segment Well, it looks like Big Sipz is shaking things up with their latest concoction—Lyte Ade. In the beverage world, where spiked seltzers and canned cocktails have run riot, Big Sipz is kicking open the door to the ready-to-drink (RTD) segment with a vodka twist. This isn't just any can; we're talking about a fancy 500ml resealable Tetra Pak...

UN Urges Real Progress on Climate at COP31 Summit

When it comes to global climate action, meetings like the COP31 summit aren’t just another day in the office. Today, in Antalya, Türkiye, the talk was big, but the stakes are even bigger as business and UN leaders grappled with the nagging gap between corporate commitments and actual emissions reductions. The Urgency of 1.5°C Folks, we're skating on thin ice here with...

Piedmont Orthopedics Expands With Spine Expert

New Talent Joins OrthoAtlanta When a spine surgeon like Dr. Avionna L. Baldwin Jefferson heads to a practice, it becomes the kind of news that ripples through both local and medical communities. Piedmont Orthopedics | OrthoAtlanta has pulled a real coup, drawing in this fellowship-trained whiz with a sharp eye for minimally invasive procedures, craning necks in Covington,...

Arbor Realty’s Legal Scramble: Hard Truths for NYSE:ABR

Reality Hits Arbor Realty Hard Well, isn't it a tangled mess over at Arbor Realty Trust, Inc.? Investors are caught in a whirlwind as a class action lawsuit reveals some murky details that many didn't see coming. Grab a chair, 'cause we're diving deep into what this could mean for you and your portfolio. What's This Legal Drama About? The lawsuit slaps Arbor Realty with...

How to Choose Between On-Site or Shop Hydraulic Repair

Hydraulic Headaches: Where's Your Fix? If there's one thing I know, it's that when hydraulic systems go belly up, you're juggling a costly mess. Not just in outright repairs, but in lost productivity. Mike Bonner, a hydraulic guru from Islip, NY, lays it out straight: when is it time to patch the problem on-site, and when do you haul it to the shop? Let's break down the...